Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy of Botox in the Treatment of Social Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* primary diagnosis of social anxiety disorder~* women of childbearing potential on an acceptable form of birth control and are not pregnant or lactating~Exclusion Criteria:~* has ever been treated with botulinum toxin A~* has another Axis I diagnosis within in the 6-months prior to screening~* history of substance abuse within 2-months of screening~* current or recent suicidality~* scoring greater than 2 on Beck Depression Inventory (BDI) suicidality question~* psychotic or bipolar disorder~* unstable medical condition~* changes in medication or psychotherapy treatment in the month prior to screening~* significant risk of committing homicide

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Open-label (Type: OTHER): 10 participants will be recruited for an open-label study. All will receive the active medication and complete depression and anxiety surveys at baseline, 4-weeks, and 8-weeks post injection. All participants will receive botulinum toxin A.
- Double-Blind (Type: PLACEBO_COMPARATOR): 30 participants will be recruited for a double-blind, comparison study. Participants will be randomized to the active or control groups. Each will receive an injection (active medication or placebo) and will complete a depression and anxiety survey at baseline, 4-weeks and 8-weeks post injection. Participants in the active group will receive botulinum toxin A; participants in the control group will receive a placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).